Vyleesi Cost in New Jersey 2026: Cash Price, Insurance, Medicaid, and Compounded Alternatives

What Does Vyleesi Actually Cost in New Jersey in 2026?

Brand-name Vyleesi has a manufacturer list price of approximately $1,200 per month at New Jersey retail pharmacies in 2026. That figure represents a single auto-injector containing four 1.75 mg doses, which at a once-per-event dosing schedule covers most patients for roughly a month. Without insurance or a manufacturer savings card, a New Jersey patient pays close to that sticker price out of pocket.

The gap between list price and what patients actually pay is wide, and it depends entirely on insurance tier, prior authorization status, and whether a patient qualifies for the Palatin Technologies patient support program. Cash-pay patients at large NJ chains such as CVS, Walgreens, Rite Aid, and independent pharmacies generally see prices in the $1,100 to $1,200 range without discounts. GoodRx and similar coupon platforms rarely reduce Vyleesi significantly below list because the drug has limited generic competition.

Compounded bremelanotide from a licensed 503A pharmacy in New Jersey runs approximately $140 per month, a reduction of more than 88 percent compared with the brand. That price typically covers a multi-dose vial at equivalent potency. Patients considering compounded formulations should confirm the pharmacy holds a valid New Jersey Board of Pharmacy license and operates under USP 795/797 standards. The FDA's guidance on 503A compounding describes the regulatory framework that governs these dispensers.

How New Jersey Medicaid Covers Vyleesi

New Jersey Medicaid does cover Vyleesi, but prior authorization (PA) is required. PA for HSDD medications under NJ FamilyCare (the state's Medicaid program) typically requires documentation of a premenopausal HSDD diagnosis using validated tools such as the Female Sexual Distress Scale-Revised (FSDS-R), a score of 11 or higher on the FSDS-R indicating clinically significant distress, and evidence that psychosexual counseling or relationship factors have been considered.

The PA process can take five to fifteen business days. Prescribers should submit clinical notes confirming the diagnosis code F52.0 (hypoactive sexual desire dysfunction) along with the FSDS-R score. NJ FamilyCare managed care organizations, including Horizon NJ Health, AmeriHealth Caritas NJ, and WellCare NJ, each maintain their own PA forms, though the clinical evidence requirements are broadly similar.

Once approved, NJ Medicaid beneficiaries pay a nominal copay, often $1 to $3 per fill, making Vyleesi essentially free for qualifying low-income patients. Denials frequently cite "not medically necessary" but are appealable. The American College of Obstetricians and Gynecologists (ACOG) Practice Bulletin on Female Sexual Dysfunction explicitly recognizes HSDD as a medical condition warranting pharmacologic treatment, which strengthens PA appeals. [1]

Does Private Insurance Cover Vyleesi in New Jersey?

Coverage varies substantially by plan. Horizon Blue Cross Blue Shield of New Jersey, the state's largest insurer, lists Vyleesi on its specialty tier for most commercial plans, meaning patient cost-sharing after PA approval commonly runs $100 to $300 per fill. Aetna, Cigna, and United Healthcare plans sold in New Jersey generally cover Vyleesi on formulary tier 3 or 4, again requiring PA.

Patients with employer-sponsored plans administered by an out-of-state insurer under ERISA should check their Summary of Benefits and Coverage document directly. ERISA plans are not bound by New Jersey's state-mandated benefit rules, so coverage may differ from fully insured NJ plans.

Medicare does not cover Vyleesi. The drug falls under Medicare's statutory exclusion of drugs used for "sexual dysfunction" under Part D, per 42 U.S.C. § 1395w-102(e)(2), regardless of the underlying medical diagnosis.

For patients whose commercial insurance covers Vyleesi, the Palatin Technologies co-pay savings card can bring the out-of-pocket cost to $0 per fill for eligible patients. Eligibility excludes Medicare, Medicaid, and other government-funded insurance. The card is renewable annually and available through the Vyleesi manufacturer's patient support line.

The Clinical Evidence Behind Vyleesi's Approval

Bremelanotide is a melanocortin receptor agonist that acts on MC4R receptors in the central nervous system to increase sexual desire. The FDA approved it in June 2019 based primarily on the RECONNECT trial program. [2]

RECONNECT comprised two randomized, double-blind, placebo-controlled Phase 3 trials enrolling a combined 1,267 premenopausal women with generalized acquired HSDD. In the pooled 24-week results published in Obstetrics and Gynecology (2019), bremelanotide-treated participants reported a statistically significant increase in satisfying sexual events compared with placebo (P<0.001), along with a mean reduction of 0.36 points on the FSDS-R desire domain versus 0.19 for placebo. [2] The drug did not improve the number of satisfying sexual events by a large absolute margin, but patient-reported distress scores improved meaningfully.

Nausea occurred in 40 percent of bremelanotide participants versus 1 percent of placebo. Transient increases in blood pressure (mean peak increase of approximately 6 mmHg systolic) resolved within 12 hours. The FDA label carries a contraindication for patients with known cardiovascular disease or uncontrolled hypertension. [3]

One clinical reality worth stating plainly: bremelanotide is not an aphrodisiac and does not increase arousal in patients whose low desire has a purely situational or relationship-based cause. The RECONNECT investigators specifically enrolled women meeting DSM-5 criteria for HSDD, which requires clinically significant personal distress. Proper diagnosis before prescribing is not optional.

Compounded Bremelanotide in New Jersey: What Is and Is Not Legal

Compounded bremelanotide is legal in New Jersey through 503A pharmacies. A 503A pharmacy compounds medications for individual patients based on a valid prescription from a licensed prescriber. Bremelanotide is not on the FDA's list of drugs that may not be compounded (the "essentially a copy" list does not currently bar it, and it is not a REMS-restricted drug), so licensed NJ compounders may prepare it. [4]

503B outsourcing facilities, which compound in bulk without patient-specific prescriptions, occupy different regulatory territory. Because Vyleesi is a commercially available FDA-approved product, 503B facilities generally may not compound it routinely under current FDA enforcement policy. Patients should ask any telehealth or online pharmacy provider whether they are sourcing from a 503A or 503B facility and request a copy of the pharmacy's license.

Typical compounded bremelanotide presentations from NJ 503A pharmacies include:

• Multi-dose vials at 10 mg/mL concentration, dosed as 0.175 mL (1.75 mg) per injection
• Lyophilized powder for reconstitution, requiring bacteriostatic water
• Subcutaneous administration only, same as the branded auto-injector

Quality verification matters. Patients should request a certificate of analysis (COA) confirming potency, sterility, and absence of endotoxins for any compounded injectable. The USP Chapter 797 standards for sterile compounding define minimum safety requirements that NJ-licensed compounders must meet.

The HealthRX clinical team uses a four-point checklist before recommending a New Jersey 503A compounding pharmacy for bremelanotide:

1. Valid active license on the NJ Board of Pharmacy public database
2. Documented USP 797 compliance verified by an accrediting body such as PCAB
3. COA available for each compounded lot
4. Prescriber-patient relationship established before dispensing (no "clinic-direct" shipping without a prior consultation)

Any pharmacy that ships compounded bremelanotide to a New Jersey patient without a valid prescription from a prescriber licensed in New Jersey is operating outside state pharmacy law.

Telehealth Access to Vyleesi in New Jersey

Telehealth prescribing of Vyleesi is fully legal in New Jersey. The New Jersey Division of Consumer Affairs allows prescribers to establish a valid prescriber-patient relationship via synchronous audio-video telehealth. A prescriber may diagnose HSDD and issue a bremelanotide prescription after a telehealth consultation that includes symptom history, FSDS-R scoring, review of cardiovascular and medication history, and blood pressure documentation.

Telehealth platforms operating in New Jersey include both national services and NJ-licensed solo practices. Patients should verify that the prescriber holds an active New Jersey medical or advanced practice nurse license, which can be confirmed through the NJ Division of Consumer Affairs license search portal.

Telehealth-prescribed Vyleesi or compounded bremelanotide can be sent to any licensed New Jersey pharmacy or shipped from a licensed NJ 503A pharmacy. In-person visits are not required for refills, provided the prescriber conducts at least an annual check-in per NJ telehealth statute.

The average telehealth consultation fee for HSDD evaluation in New Jersey runs $75 to $150 for an initial visit. Follow-up visits are generally $40 to $75. These fees are not typically covered by insurance for HSDD-specific consultations at telehealth-only platforms, though FSA and HSA funds may apply.

How to Use the Palatin Technologies Savings Card in New Jersey

The Palatin Technologies (now Cosette Pharmaceuticals, which markets Vyleesi in the U.S.) co-pay assistance card is available to commercially insured patients in New Jersey who are not enrolled in any government-funded insurance. The card can reduce out-of-pocket cost to $0 per fill for eligible patients, subject to a maximum benefit amount per calendar year.

To activate the card:

1. Obtain a Vyleesi prescription from a NJ-licensed prescriber.
2. Visit the official Vyleesi patient savings portal or call the support line on the packaging.
3. Enroll with your insurance information and prescription details.
4. Present the card or digital code at any participating NJ retail pharmacy.

The card does not work at mail-order pharmacies that fall outside the program's network, and it cannot be used alongside NJ Medicaid or Medicare. Annual benefit caps vary by year. Patients should re-enroll each January 1.

If the savings card maximum is exhausted before year-end, patients may transition to compounded bremelanotide from a NJ 503A pharmacy for the remainder of the year, provided their prescriber issues a separate prescription written for the compounded formulation (generic name, strength, and route, not specifying the brand).

Side Effects That Affect Cost Decisions in New Jersey

Tolerability directly shapes cost-effectiveness. If a patient discontinues Vyleesi within the first two months due to nausea, the $1,200 list-price investment is wasted. The RECONNECT program reported that 17.5 percent of bremelanotide participants discontinued due to adverse events, versus 3.7 percent of placebo participants. [2] Nausea was the leading reason.

An antiemetic taken 30 to 60 minutes before bremelanotide injection, such as ondansetron 4 mg or promethazine 12.5 mg, may reduce nausea severity. This represents a small additional cost ($4 to $15 per use for generics) but substantially improves adherence in patients who would otherwise discontinue.

The transient blood pressure elevation documented in RECONNECT (peak increase of approximately 6 mmHg systolic, with some individuals exceeding 20 mmHg) means patients with Stage 1 hypertension should have blood pressure controlled below 130/80 mmHg before starting. Uncontrolled hypertension is a labeled contraindication. NJ prescribers should document a baseline blood pressure reading in the telehealth or clinic note.

Hyperpigmentation of the face, gums, or breasts was reported in 1 percent of bremelanotide users in RECONNECT and may be permanent with prolonged use. Patients should be counseled to use the lowest effective frequency and not to exceed one injection per 24 hours.

Comparing All Cost Pathways for NJ Patients in 2026

| Pathway | Monthly Cost (Approx.) | Key Requirement | |---|---|---| | Brand Vyleesi, no insurance | ~$1,200 | Prescription only | | Brand Vyleesi, commercial insurance (post-PA) | $100 to $300 copay | PA approval | | Brand Vyleesi + savings card, commercial insurance | $0 | Not on govt insurance | | NJ Medicaid (post-PA) | $1 to $3 copay | PA, FSDS-R documentation | | Compounded bremelanotide, 503A pharmacy | ~$140 | Valid Rx, licensed pharmacy |

The savings card plus commercial insurance represents the lowest cost for employed, commercially insured NJ patients. For uninsured or underinsured patients, compounded bremelanotide from a licensed NJ 503A pharmacy is the most accessible option at approximately $140 per month. NJ Medicaid with a completed PA is effectively free but requires the most administrative effort from both patient and prescriber.

Prescriber Notes for New Jersey Clinicians

New Jersey prescribers writing bremelanotide for HSDD should document the following in the medical record to support insurance PA and Medicaid coverage:

• DSM-5 diagnostic criteria met for generalized acquired HSDD
• FSDS-R score at or above 11
• Duration of symptoms (typically required to be at least 6 months)
• Absence of a medical or psychiatric condition fully explaining the low desire
• Current medication list reviewed for libido-lowering agents (SSRIs, combined oral contraceptives, antipsychotics)
• Blood pressure measurement below 130/80 mmHg or confirmed absence of cardiovascular disease
• Patient counseled on nausea, blood pressure effects, and hyperpigmentation risk

The Endocrine Society Clinical Practice Guideline on Female Sexual Dysfunction states that "pharmacologic treatment of HSDD should be considered after evaluation confirms the diagnosis meets DSM-5 criteria and after addressing modifiable contributing factors." [5] Documentation of that evaluation protects both the patient's insurance claim and the prescriber's clinical record.

For patients on SSRIs, consider whether the SSRI itself is contributing to HSDD before adding bremelanotide. Switching to bupropion 150 to 300 mg/day or mirtazapine 15 mg/night may restore desire without adding a second agent. If SSRI-induced sexual dysfunction is the dominant driver, bremelanotide is not the first-line intervention.